AbobotulinumtoxinA: evidence for long duration of response
Objective: To assess clinical treatment intervals and duration of response for abobotulinumtoxinA in the management of pediatric and adult spasticity and assess preclinical data that…An examination of real-world onabotulinumtoxinA utilization for the treatment of upper limb spasticity: The Adult Spasticity International Registry (ASPIRE) study
Objective: To explore real-world patterns of onabotulinumtoxinA utilization in patients with upper limb spasticity over 2 years. Background: OnabotulinumtoxinA treatment for spasticity is variable, as…Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs in spastic hemiparesis: baseline data from the ENGAGE study
Objective: To report baseline data from ENGAGE, an international phase 3b/4, prospective, single-arm, open-label study (NCT02969356) conducted in France, the Czech Republic, Russia and the USA.…The effect of Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs on voluntary movements in adults with spastic hemiparesis
Objective: To report primary outcomes from ENGAGE, an international phase 3b/4, prospective, single-arm, open-label study (NCT02969356). Background: ENGAGE assessed effects of Guided Self-rehabilitation Contracts (GSC)…Is teleneurology effective in screening for spasticity?
Objective: To test the effectiveness of teleneurology for spasticity screening. Background: Spasticity is underdiagnosed and can pose significant problems when not treated. Unfortunately, according to…OnabotulinumtoxinA Reduces Disability in Treatment-Naive Adult Patients with Spasticity: Results from the ASPIRE Study
Objective: Examine real-world onabotulinumtoxinA utilization and effectiveness over 2 years in patients naive or non-naive to botulinum toxins for spasticity from the Adult Spasticity International…Successful late rehabilitation based on botulinum therapy
Objective: Hemiparesis of various severity is the most common stroke side effect. On average 30-40% of stroke survivors develop post-stroke spasticity. The best neuroplasticity enabling…Hereditary spastic paraplegia 11 is easy to be misdiagnosed as adult metachromatic leukodystrophy
Objective: To report a case of a 32-year-old woman with progressive spastic paraparesis who was misdiagnosed initially as adult onset metachromatic leukodystrophy (MLD) Background: MLD…Natural History of Movement Abnormalities on Hereditary Spastic Paraplegia: validation of timed functional instruments
Objective: To evaluate the natural history of Hereditary Spastic Paraplegia (HSPs) and to define sensitivity to change, minimal clinically important difference (MCID) and validity of…Characterization of the motor phenotype and striatal muscle analysis in a mouse model of hereditary spasticity
Objective: Characterize the motor phenotype and contractile force characteristics of skeletal plantar flexor muscles in a mutant mouse model for spasticity. This model displays a…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.